JP2025504382A5 - - Google Patents
Info
- Publication number
- JP2025504382A5 JP2025504382A5 JP2024540933A JP2024540933A JP2025504382A5 JP 2025504382 A5 JP2025504382 A5 JP 2025504382A5 JP 2024540933 A JP2024540933 A JP 2024540933A JP 2024540933 A JP2024540933 A JP 2024540933A JP 2025504382 A5 JP2025504382 A5 JP 2025504382A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025118767A JP2025160251A (ja) | 2022-01-21 | 2025-07-15 | １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267018P | 2022-01-21 | 2022-01-21 | |
| US63/267,018 | 2022-01-21 | ||
| PCT/US2023/060944 WO2023141536A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025118767A Division JP2025160251A (ja) | 2022-01-21 | 2025-07-15 | １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2025504382A JP2025504382A (ja) | 2025-02-12 |
| JP2025504382A5 true JP2025504382A5 (https=) | 2025-06-09 |
| JPWO2023141536A5 JPWO2023141536A5 (https=) | 2025-06-09 |
| JP7714811B2 JP7714811B2 (ja) | 2025-07-29 |
Family
ID=85382827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540933A Active JP7714811B2 (ja) | 2022-01-21 | 2023-01-20 | １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 |
| JP2025118767A Pending JP2025160251A (ja) | 2022-01-21 | 2025-07-15 | １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025118767A Pending JP2025160251A (ja) | 2022-01-21 | 2025-07-15 | １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11964990B2 (https=) |
| EP (1) | EP4466273A1 (https=) |
| JP (2) | JP7714811B2 (https=) |
| KR (1) | KR20240136972A (https=) |
| CN (1) | CN119053610A (https=) |
| AR (1) | AR128310A1 (https=) |
| AU (1) | AU2023210279A1 (https=) |
| CA (1) | CA3242074A1 (https=) |
| CO (1) | CO2024009334A2 (https=) |
| IL (1) | IL312709A (https=) |
| MX (1) | MX2024008840A (https=) |
| TW (1) | TW202340210A (https=) |
| WO (1) | WO2023141536A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
| CN117820134A (zh) * | 2024-01-10 | 2024-04-05 | 山东盛安贝新材料有限公司南京分公司 | 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| KR20220158725A (ko) | 2020-02-24 | 2022-12-01 | 광조우 루펭 파마슈티칼 컴퍼니 엘티디. | Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체 |
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
-
2023
- 2023-01-19 US US18/156,987 patent/US11964990B2/en active Active
- 2023-01-19 TW TW112102814A patent/TW202340210A/zh unknown
- 2023-01-20 AU AU2023210279A patent/AU2023210279A1/en active Pending
- 2023-01-20 WO PCT/US2023/060944 patent/WO2023141536A1/en not_active Ceased
- 2023-01-20 CA CA3242074A patent/CA3242074A1/en active Pending
- 2023-01-20 AR ARP230100132A patent/AR128310A1/es unknown
- 2023-01-20 MX MX2024008840A patent/MX2024008840A/es unknown
- 2023-01-20 KR KR1020247023725A patent/KR20240136972A/ko active Pending
- 2023-01-20 JP JP2024540933A patent/JP7714811B2/ja active Active
- 2023-01-20 CN CN202380016422.5A patent/CN119053610A/zh active Pending
- 2023-01-20 IL IL312709A patent/IL312709A/en unknown
- 2023-01-20 EP EP23707582.5A patent/EP4466273A1/en active Pending
-
2024
- 2024-03-05 US US18/595,898 patent/US20250066388A1/en not_active Abandoned
- 2024-07-15 CO CONC2024/0009334A patent/CO2024009334A2/es unknown
-
2025
- 2025-07-02 US US19/258,642 patent/US20260028356A1/en active Pending
- 2025-07-15 JP JP2025118767A patent/JP2025160251A/ja active Pending